BR112014005788A2 - variante de antitripsina alfa-1, método de preparação da mesma e aplicação da mesma - Google Patents

variante de antitripsina alfa-1, método de preparação da mesma e aplicação da mesma

Info

Publication number
BR112014005788A2
BR112014005788A2 BR112014005788A BR112014005788A BR112014005788A2 BR 112014005788 A2 BR112014005788 A2 BR 112014005788A2 BR 112014005788 A BR112014005788 A BR 112014005788A BR 112014005788 A BR112014005788 A BR 112014005788A BR 112014005788 A2 BR112014005788 A2 BR 112014005788A2
Authority
BR
Brazil
Prior art keywords
variant
preparation
application
antitrypsin
alfa
Prior art date
Application number
BR112014005788A
Other languages
English (en)
Other versions
BR112014005788B1 (pt
Inventor
Chung Hye-Shin
Sun Kim Ji
Mee Lee Sang
Jae Park Soon
Original Assignee
Alteogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alteogen Inc filed Critical Alteogen Inc
Publication of BR112014005788A2 publication Critical patent/BR112014005788A2/pt
Publication of BR112014005788B1 publication Critical patent/BR112014005788B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Crystallography & Structural Chemistry (AREA)

Abstract

ÿþr
BR112014005788-5A 2011-09-15 2012-08-13 variante de antitrispsina alfa-1, método de preparação da mesma, composição farmacêutica compreendendo a mesma fusão de variante de antitrispsina alfa-1 BR112014005788B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2011-0092819 2011-09-15
KR20110092819 2011-09-15
KR10-2012-0058998 2012-06-01
KR1020120058998A KR101402702B1 (ko) 2011-09-15 2012-06-01 신규한 알파-1 안티트립신 변이체, 이의 제조방법 및 용도
PCT/KR2012/006441 WO2013039295A1 (ko) 2011-09-15 2012-08-13 신규한 알파-1 안티트립신 변이체, 이의 제조방법 및 용도

Publications (2)

Publication Number Publication Date
BR112014005788A2 true BR112014005788A2 (pt) 2017-03-28
BR112014005788B1 BR112014005788B1 (pt) 2021-01-12

Family

ID=48179554

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014005788-5A BR112014005788B1 (pt) 2011-09-15 2012-08-13 variante de antitrispsina alfa-1, método de preparação da mesma, composição farmacêutica compreendendo a mesma fusão de variante de antitrispsina alfa-1

Country Status (11)

Country Link
US (1) US9051395B2 (pt)
EP (1) EP2757110B1 (pt)
JP (1) JP6001074B2 (pt)
KR (1) KR101402702B1 (pt)
CN (1) CN103827141B (pt)
AU (1) AU2012309292B2 (pt)
BR (1) BR112014005788B1 (pt)
CA (1) CA2848919C (pt)
MX (1) MX349364B (pt)
RU (1) RU2567007C1 (pt)
WO (1) WO2013039295A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104379598B (zh) * 2012-06-05 2017-04-05 Cj医药健康株式会社 高度糖基化的长效人生长激素蛋白及其生产方法
WO2019125002A1 (ko) 2017-12-20 2019-06-27 (주)알테오젠 신규한 성장 호르몬 수용체 길항제 및 이의 융합 단백질
KR102167827B1 (ko) * 2017-12-20 2020-10-20 주식회사 알테오젠 신규한 성장 호르몬 수용체 길항제 및 이의 융합 단백질
CN112839964A (zh) * 2018-06-07 2021-05-25 普泰公司 包含融合蛋白的药物组合物及其用途
KR102134571B1 (ko) * 2018-06-15 2020-07-16 주식회사 알테오젠 혈액응고인자 VII/VIIa 융합단백질의 제조 방법
CA3103920A1 (en) 2018-06-22 2019-12-26 Ucl Business Ltd Compounds for treating alpha-1 antitrypsin-mediated diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2163081C (en) * 1993-05-18 2000-03-14 Myeong-Hee Yu Thermoresistant alpha-1-antitrypsin mutein
KR0133252B1 (ko) * 1993-05-18 1998-04-14 김은영 내열성의 알파-1-안티트립신 뮤테인
RU2392963C2 (ru) * 2004-08-09 2010-06-27 Элиоз Байофарма, Инк. Синтетические варианты гипергликозилированного протеазо-резистентного полипептида, пероральные композиции и способы применения таких вариантов
WO2008151845A2 (en) * 2007-06-15 2008-12-18 Charite - Universitätsmedizin Berlin Methods for producing glycosylated human alpha-1 antitrypsin (a1at) in mammalian host cells
CN102439044B (zh) * 2009-04-22 2014-08-13 阿特根公司 通过体内持续释放维持的体内半衰期增加的融合蛋白质或融合肽以及使用所述融合蛋白质或融合肽增加体内半衰期的方法
CN104379598B (zh) * 2012-06-05 2017-04-05 Cj医药健康株式会社 高度糖基化的长效人生长激素蛋白及其生产方法

Also Published As

Publication number Publication date
WO2013039295A1 (ko) 2013-03-21
CN103827141B (zh) 2016-01-13
MX349364B (es) 2017-07-26
CA2848919C (en) 2016-09-13
KR101402702B1 (ko) 2014-06-05
EP2757110A1 (en) 2014-07-23
AU2012309292A1 (en) 2014-04-24
CA2848919A1 (en) 2013-03-21
US9051395B2 (en) 2015-06-09
US20140371160A1 (en) 2014-12-18
BR112014005788B1 (pt) 2021-01-12
CN103827141A (zh) 2014-05-28
KR20130029713A (ko) 2013-03-25
AU2012309292B2 (en) 2015-05-07
EP2757110A4 (en) 2015-04-22
JP6001074B2 (ja) 2016-10-05
JP2014534166A (ja) 2014-12-18
EP2757110B1 (en) 2017-09-27
RU2567007C1 (ru) 2015-10-27
RU2014114790A (ru) 2015-10-20
MX2014003183A (es) 2015-01-12

Similar Documents

Publication Publication Date Title
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
CO7061081A2 (es) Derivados macrocíclicos para el tratamiento de enfermedades
BR112013021368A2 (pt) implante, especialmente para oclusão de abeurismas bifurcais
BR112013033811A2 (pt) composição, método de preparação da composição, e, composto
BR112013030472A2 (pt) formulação farmacêutica, artigo de fabricação e método
DK3251678T3 (da) Benzoxaborolderivater til behandling af bakterieinfektioner
BR112014007203A2 (pt) composto, composição farmacêutica, método de tratamento, utilização de um composto, conjunto e invenção
BR112014008126A2 (pt) composto, método para o tratamento, composição farmacêutica, utilização de um composto e invenção
DK3513793T3 (da) Heterocyclylaminer som pi3k-inhibitorer
DK2710018T3 (da) Makrocykliske forbindelser som proteinkinasehæmmere
BR112014010164A2 (pt) implante de tecido duro
DK2872497T4 (da) Chromanyl-derivater til behandling af mitokondriel sygdom
BR112013023674A2 (pt) inibidores potentes e seletivos de nav1.3 e nav1.7
BR112014011685A2 (pt) composto, utilização de um composto e método
CO6970598A2 (es) Derivados de 4-pregenen-11ss-17-21-triol-3,20-diona para el tratamiento de afecciones oculares
BR112012023355A2 (pt) composto, composição farmacêutica e método de ruptura da interação nek2/hec1
EP2742033A4 (en) FLAVONOID COMPOUNDS AND METHODS OF USE
BR112014013614A2 (pt) composição antimicrobiana, método para desinfetar uma superfície e uso de uma composição
CO6821934A2 (es) Composición de androgeno para tratar una afección oftalmica
SMT201600059B (it) Trattamento di infezioni da streptococco
BR112014005788A2 (pt) variante de antitripsina alfa-1, método de preparação da mesma e aplicação da mesma
CL2014001883A1 (es) Compuestos y métodos para el tratamiento de las infecciones de candidiasis y aspergillus
BR112014016736A2 (pt) composto, composição farmacêutica, método para tratamento, uso de um composto e invenção
SMT201500310B (it) Metodo per la prevenzione e il trattamento della sepsi
EP3013329A4 (en) Method of treating intracellular infection

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/08/2012, OBSERVADAS AS CONDICOES LEGAIS.